Cycloastragenol Clinical Trials

Size	Price	Qty
25mg	USD 147
1g	USD 970

Clinical Trials

Several clinical trials evaluate conditions relevant to Cycloastragenol research, including Alzheimer's disease, acute ST-elevation myocardial infarction, Chopra-Amiel-Gordon syndrome, and periodontal diseases. Encompassing Phase 2 and non-applicable phase classifications, these actively recruiting and completed studies investigate cognitive function, retinal amyloid markers, rapid myocardial infarction identification, and periodontal tissue preservation. These initiatives are primarily sponsored by academic and medical institutions.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05777083	Recruiting	ST Elevation Myocardial Infarction\|Electrocardiogram	Ewha Womans University Mokdong Hospital	2023-01-01	Not Applicable
NCT05578443	Recruiting	Alzheimer''s Disease	Fujian Medical University Union Hospital	2022-10-01	Phase 2
NCT05528744	Recruiting	Genetic Disease\|Chopra-Amiel-Gordon Syndrome\|CAGS\|ANKRD17	Boston Children''s Hospital	2022-08-27	--
NCT05533528	Recruiting	Periodontal Pocket\|Periodontal Diseases\|Periodontal Bone Loss	Universidad de Murcia	2022-05-03	Not Applicable
NCT05118009	Completed	Myocardial Infarction Acute	National Defense Medical Center Taiwan	2022-05-01	Not Applicable
NCT02530255	COMPLETED	Alzheimer Disease	Chippewa Valley Eye Clinic	2016-12-01

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Cycloastragenol product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Cycloastragenol functions as a potent telomerase activator that stimulates telomerase enzymatic activity, thereby promoting telomere elongation and suppressing cellular senescence pathways. This enhancement of cellular lifespan and survival supports neuronal protection and tissue maintenance, demonstrating potential relevance in clinically studied conditions such as Alzheimer's disease and myocardial infarction.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).